About Goodwin Biotechnology
Goodwin Biotechnology is a private company based in Plantation, Florida. It has reported $30,725,002 raised in four offerings on Form D since April 2019. Its chief executive is Karl Pinto.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 5, 2025 | Jan 27, 2026 | $2,000,000of $4.0M target | 2 | $1.0M | Debt, Options, Securities on exerciseRule 506(b), 4a5 | Form D ↗ |
| Nov 1, 2024 | Nov 12, 2024 | $3,000,000fully sold | 1 | $3.0M | Debt, Options, Securities on exerciseRule 506(b), 4a5 | Form D ↗ |
| Sep 12, 2023 | Oct 2, 2023 | $5,000,002fully sold | 3 | $1.6M | Equity, Options, Securities on exerciseRule 506(b), 4a5 | Form D ↗ |
| Apr 18, 2019 | Apr 30, 2019 | $20,725,000fully sold | 5 | $4.1M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $30,725,002 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Goodwin Biotechnology's Form D filed Jan 27, 2026.
Earlier filings also listed Darrin Schellin (chief executive officer and director, last listed Oct 2023), Sunil Agarwal (financial controller and treasurer, last listed Apr 2019), SooYoung Lee (chief operating officer and secretary, last listed Apr 2019), Maria Menezes (director, last listed Apr 2019), Jerry Liao (director, last listed Apr 2019) and Cesar Menezes (director, last listed Apr 2019).